A series of new studies led by scientists at The Scripps Research Institute and the International AIDS Vaccine Initiative describe a potential vaccination strategy to jump-start the selection and evolution of broadly effective antibodies to prevent HIV infection. The researchers plan to test this strategy in an upcoming human clinical trial.
New approaches that could spur the human body to produce HIV-blocking antibodies have been successful in mice mimicking the human immune system, according to five studies published today in the research journals Cell, Immunity and Science.
Kymab, the Scripps Research Institute, and the International AIDS Vaccine Initiative show that a novel approach using Kymouse, a modified mouse that mimics human antibody responses, and an immunogen of HIV-protein nanoparticles is an effective platform for discovering and testing possible HIV vaccines. Immunized mice produced human antibodies against the virus protein, the first proof of principle that this strategy can work, triggering the response required to test components of a future vaccine.
During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection. With an eye towards developing a vaccine, in four related papers from multiple groups publishing Sept. 8 in Cell and Immunity, researchers describe a multi-step method for 'training' the immune system to produce these antibodies in genetically engineered mice.
Researchers at Boston Children's Hospital have developed a technology to quickly generate mouse models for testing and tweaking potential HIV vaccines.
A new study indicates that early infant circumcision, which helps to prevent HIV transmission later in life, can be safely performed in rural Uganda.
A new study by researchers at Columbia University's Mailman School of Public Health reports that the Earned Income Tax Credit program is not only good for people's pocketbooks, but also for their health. Findings showed that the program is much more cost-effective than many health interventions and has the added benefit of reversing mortality trends among low-income Americans in some states that have been experiencing increases in mortality in recent years.
A research collaboration between groups in Japan, China, France, Kazakhstan, and the UK has discovered that a single T cell-selected HIV mutation can produce different T cell adaptations. The finding demonstrates that the complexity of the HIV/T cell co-evolution is much higher than previously thought.
Tulane University researchers found some monkeys whose immune systems are depleted by the simian strain of HIV have a second line of defense against tuberculosis. The discovery could have significant impacts on future vaccines for TB.
Researchers have shown how anti-HIV protein inhibitor drugs can bind to the wrong protein, causing unwanted side effects.